Biora Therapeutics Stock Fundamentals
| BIOR Stock | USD 1.67 0.04 2.45% |
Biora Therapeutics fundamentals help investors to digest information that contributes to Biora Therapeutics' financial success or failures. It also enables traders to predict the movement of Biora Stock. The fundamental analysis module provides a way to measure Biora Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biora Therapeutics stock.
At this time, Biora Therapeutics' Tax Provision is relatively stable compared to the past year. As of 11/24/2024, Interest Expense is likely to grow to about 11.5 M, while Depreciation And Amortization is likely to drop slightly above 527.2 K. Biora | Select Account or Indicator |
Biora Therapeutics Company Shares Outstanding Analysis
Biora Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biora Therapeutics Shares Outstanding | 4.52 M |
Most of Biora Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biora Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biora Shares Outstanding Historical Pattern
Today, most investors in Biora Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biora Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biora Therapeutics shares outstanding as a starting point in their analysis.
Biora Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Biora Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Biora Therapeutics has 4.52 M of shares currently outstending. This is 97.49% lower than that of the Biotechnology sector and 95.77% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.21% higher than that of the company.
Biora Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biora Therapeutics's current stock value. Our valuation model uses many indicators to compare Biora Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biora Therapeutics competition to find correlations between indicators driving Biora Therapeutics's intrinsic value. More Info.Biora Therapeutics is rated below average in return on asset category among its peers. It is rated fifth in operating margin category among its peers . At this time, Biora Therapeutics' Operating Profit Margin is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Biora Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Biora Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biora Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biora Therapeutics could also be used in its relative valuation, which is a method of valuing Biora Therapeutics by comparing valuation metrics of similar companies.Biora Therapeutics is currently under evaluation in shares outstanding category among its peers.
Biora Fundamentals
| Return On Asset | -1.25 | ||||
| Operating Margin | (49.64) % | ||||
| Current Valuation | 44 M | ||||
| Shares Outstanding | 4.52 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 29.39 % | ||||
| Number Of Shares Shorted | 201.8 K | ||||
| Price To Sales | 8.78 X | ||||
| Revenue | 4 K | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (114.05 M) | ||||
| Net Income | (124.11 M) | ||||
| Cash And Equivalents | 37.06 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 47.43 M | ||||
| Current Ratio | 1.69 X | ||||
| Book Value Per Share | (36.43) X | ||||
| Cash Flow From Operations | (48.5 M) | ||||
| Short Ratio | 2.94 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 34.0 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 7.55 M | ||||
| Total Asset | 31.21 M | ||||
| Retained Earnings | (950.96 M) | ||||
| Working Capital | (43.9 M) | ||||
| Current Asset | 667 K | ||||
| Current Liabilities | 3.01 M | ||||
| Net Asset | 31.21 M |
About Biora Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biora Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biora Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biora Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 542 K | 514.9 K | |
| Total Revenue | 4 K | 3.8 K | |
| Cost Of Revenue | 555 K | 527.2 K | |
| Stock Based Compensation To Revenue | 4.1 K | 4.3 K | |
| Sales General And Administrative To Revenue | 49.47 | 51.94 | |
| Research And Ddevelopement To Revenue | 7.5 K | 7.8 K | |
| Capex To Revenue | 25.75 | 27.04 | |
| Ebit Per Revenue | -16.8 K | -15.9 K |
Pair Trading with Biora Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biora Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biora Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Biora Stock
| 0.61 | A | Agilent Technologies Earnings Call Tomorrow | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.83 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Biora Stock
| 0.65 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.5 | KZR | Kezar Life Sciences | PairCorr |
| 0.44 | RNXT | RenovoRx | PairCorr |
| 0.41 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Biora Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biora Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biora Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biora Therapeutics to buy it.
The correlation of Biora Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biora Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biora Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biora Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Biora Stock Analysis
When running Biora Therapeutics' price analysis, check to measure Biora Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biora Therapeutics is operating at the current time. Most of Biora Therapeutics' value examination focuses on studying past and present price action to predict the probability of Biora Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biora Therapeutics' price. Additionally, you may evaluate how the addition of Biora Therapeutics to your portfolios can decrease your overall portfolio volatility.